151 related articles for article (PubMed ID: 38483130)
1. Central nervous system adverse events of immune checkpoint inhibitors.
Farina A; Villagrán-García M; Vogrig A; Joubert B
Curr Opin Neurol; 2024 Jun; 37(3):345-352. PubMed ID: 38483130
[TBL] [Abstract][Full Text] [Related]
2. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
[TBL] [Abstract][Full Text] [Related]
3. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
[TBL] [Abstract][Full Text] [Related]
5. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
6. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
8. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system complications associated with immune checkpoint inhibitors.
Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
[TBL] [Abstract][Full Text] [Related]
10. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
Suzuki S
Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
[TBL] [Abstract][Full Text] [Related]
11. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment.
Marsili L; Marcucci S; LaPorta J; Chirra M; Espay AJ; Colosimo C
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239077
[TBL] [Abstract][Full Text] [Related]
14. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
16. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
17. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
[TBL] [Abstract][Full Text] [Related]
18. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
19. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
[TBL] [Abstract][Full Text] [Related]
20. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]